HK1053053B - Use of retinoid receptor antagonists or agonists in the treatment of rickets and other bone diseases - Google Patents

Use of retinoid receptor antagonists or agonists in the treatment of rickets and other bone diseases Download PDF

Info

Publication number
HK1053053B
HK1053053B HK03105084.3A HK03105084A HK1053053B HK 1053053 B HK1053053 B HK 1053053B HK 03105084 A HK03105084 A HK 03105084A HK 1053053 B HK1053053 B HK 1053053B
Authority
HK
Hong Kong
Prior art keywords
bone
retinoid receptor
cartilage
ossification
treatment
Prior art date
Application number
HK03105084.3A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1053053A1 (en
Inventor
Pacifici Maurizio
A. Chandraratna Roshantha
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of HK1053053A1 publication Critical patent/HK1053053A1/en
Publication of HK1053053B publication Critical patent/HK1053053B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
HK03105084.3A 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of rickets and other bone diseases HK1053053B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/552,823 2000-04-20
US09/552,823 US20030114482A1 (en) 1999-12-15 2000-04-20 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
PCT/US2001/012742 WO2001080894A2 (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies

Publications (2)

Publication Number Publication Date
HK1053053A1 HK1053053A1 (en) 2003-10-10
HK1053053B true HK1053053B (en) 2005-06-10

Family

ID=24206947

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03105084.3A HK1053053B (en) 2000-04-20 2001-04-19 Use of retinoid receptor antagonists or agonists in the treatment of rickets and other bone diseases

Country Status (9)

Country Link
US (1) US20030114482A1 (OSRAM)
EP (1) EP1274456B1 (OSRAM)
JP (1) JP2003531180A (OSRAM)
AT (1) ATE285794T1 (OSRAM)
AU (3) AU2001255488B2 (OSRAM)
CA (1) CA2407021A1 (OSRAM)
DE (1) DE60108094T2 (OSRAM)
HK (1) HK1053053B (OSRAM)
WO (1) WO2001080894A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE423761T1 (de) * 2003-12-26 2009-03-15 Allergan Inc Disubstituierte chalcogenoxime mit antagonistischer wirkung am rar(gamma)- retinoidrezeptor
JP2007070281A (ja) * 2005-09-06 2007-03-22 Matsumoto Shika Univ レチノイドｘ受容体関連化合物を用いた骨粗鬆症の治療剤
CA2667091C (en) * 2005-12-13 2014-06-10 Mcgill University Method for correcting a lipid imbalance in a subject
US20090209601A1 (en) * 2008-02-15 2009-08-20 Wyeth Use of rxr agonists for the treatment of osteoarthritis
PL2613776T3 (pl) 2010-09-01 2021-01-11 Thomas Jefferson University Kompozycja oraz sposób naprawy i regeneracji mięśni
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
CN109589324B (zh) 2012-11-08 2022-06-14 国立大学法人山口大学 角结膜病症的治疗剂
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
CN105377258B (zh) 2013-05-22 2020-08-28 国立大学法人山口大学 视网膜脉络膜病症的抑制剂
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
BR112019009929A2 (pt) 2016-11-16 2019-08-20 Clementia Pharmaceuticals Inc métodos para inibir a formação de um osteocondroma, para reduzir o tamanho de um osteocondroma, para desacelerar o crescimento de um osteocondroma e para reduzir hiperplasia de cartilagem
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5648514A (en) * 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
DE19501032A1 (de) * 1995-01-14 1996-07-18 Max Delbrueck Centrum Mittel zur Behandlung von rheumatischen Erkrankungen
US5776699A (en) * 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) * 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6121309A (en) * 1996-03-18 2000-09-19 Eisai Co., Ltd. Fused-ring carboxylic acid derivatives
US5763635A (en) * 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) * 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity
CA2254429A1 (en) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions for promoting chondrogenesis
DE19910246A1 (de) * 1999-03-08 2000-09-28 Bayer Ag Trennfreundliche Polyurethan-Formschaum-Systeme
AU784377B2 (en) * 2000-03-14 2006-03-23 Arthur V. Sampaio Compositions and methods for affecting osteogenesis

Also Published As

Publication number Publication date
EP1274456B1 (en) 2004-12-29
AU2001255488B2 (en) 2006-07-27
US20030114482A1 (en) 2003-06-19
WO2001080894A2 (en) 2001-11-01
JP2003531180A (ja) 2003-10-21
WO2001080894A3 (en) 2002-07-25
CA2407021A1 (en) 2001-11-01
DE60108094T2 (de) 2005-12-15
HK1053053A1 (en) 2003-10-10
DE60108094D1 (de) 2005-02-03
EP1274456A2 (en) 2003-01-15
AU2006233216A1 (en) 2006-11-16
AU5548801A (en) 2001-11-07
ATE285794T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
EP1274456B1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
EP1248602B1 (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
Wang et al. The role of autophagy in bone metabolism and clinical significance
JP2003526677A (ja) 骨形成に影響を与える組成物および方法
US7608281B2 (en) Composition and use of RAR antagonists for promoting chondrogenesis
JP2001515864A (ja) 非天然ｆｐ選択的作用薬を使用した骨体積増加方法
AU2001255488A1 (en) Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
KR20060015727A (ko) 모다피닐과 또 다른 약물을 포함하는 약제학적 배합물
EP1542700B1 (en) Zoledronic acid for preventing or reducing secondary fractures after hip fracture
DE3033545A1 (de) Verwendung bekannter antiallergener mittel bei der bekaempfung von pathologischen mineralresorptionszustaenden
WO2007149816A2 (en) Strontium compositions and methods of treating osteoporotic conditions
WO2004110458A1 (en) Phenothiazine enantiomers as agents for the prevention of bone loss
CN117281921A (zh) TF@Pt-Aln纳米颗粒及其制备方法和应用
RU2827071C1 (ru) Средство для лечения дегенеративных процессов опорно-двигательного аппарата
EP1733722A1 (en) Memory fixation accelerator
JP2002538105A (ja) 骨体積の増加のための天然に存在しないｅｐ１選択的アゴニストの使用
HK1089112A (en) Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20110021560A1 (en) Compositions And Methods For Regulating Chondrocyte Proliferation In Bone Disorders
WO2023117855A1 (en) Use of analog of c-type natriuretic peptide for the treatment of fgfr-related bone repair and bone formation impairment
HK1064043B (en) Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis or chondromalacia
HK1079431B (en) Zoledronic acid for preventing or reducing secondary fractures after hip fracture
MXPA00002395A (en) Method of increasing bone volume
WO2002096403A1 (en) Composition containing 2-aminophenylacetic acid
JP2002538122A (ja) 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090419